SCHEMBL2294293

SCHEMBL2294293

O=C(Nc1ccc(F)cc1)ON=C1CCN(C(=O)Nc2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.50
LMNA P02545 5/20 0.49
MAPT P10636 4/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
RECQL P46063 1/20 0.49
HPGDS O60760 1/20 0.48
GAA P10253 3/20 0.47
HSD17B10 Q99714 1/20 0.47
UBE2M P61081 1/20 0.47
DCUN1D1 Q96GG9 1/20 0.47
FAAH O00519 1/20 0.47
TRPV1 Q8NER1 3/20 0.46
EPHX2 P34913 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GOT1 P17174 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294335 0.90 RAB9A (0.58) GRIN2BLMNAMAPTHTTSMN1; SMN2
SCHEMBL2291227 0.86 HPGDS (0.53) LMNASMN1; SMN2KMT2AMEN1HPGDS
SCHEMBL2294464 0.85 TRPV1 (0.44) LMNAMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL2297093 0.84 KMT2A (0.54) LMNAMAPTHTTSMN1; SMN2KMT2A
SCHEMBL2289626 0.84 TSHR (0.45) GRIN2BLMNAMAPTHTTSMN1; SMN2
SCHEMBL2292379 0.81 TSHR (0.50) LMNAMAPTHTTSMN1; SMN2KMT2A
SCHEMBL3634402 0.81 KMT2A (0.39) GRIN2BLMNAMAPTHTTSMN1; SMN2
SCHEMBL8098770 0.80 LMNA (0.57) GRIN2BLMNAMAPTHTTKMT2A
SCHEMBL3640469 0.77 RAB9A (0.55) LMNAMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL2292202 0.76 MEN1 (0.50) LMNAMAPTHTTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S GRIN2B 534/4885LMNA 2476/4885MAPT 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.